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Abstract
Background: Predicting vesico-ureteral reflux (VUR) $3 at the time of the first urinary tract infection (UTI) would make it
possible to restrict cystography to high-risk children. We previously derived the following clinical decision rule for that
purpose: cystography should be performed in cases with ureteral dilation and a serum procalcitonin level $0.17 ng/mL, or
without ureteral dilatation when the serum procalcitonin level $0.63 ng/mL. The rule yielded a 86% sensitivity with a 46%
specificity. We aimed to test its reproducibility.
Study Design: A secondary analysis of prospective series of children with a first UTI. The rule was applied, and predictive
ability was calculated.
Results: The study included 413 patients (157 boys, VUR $3 in 11%) from eight centers in five countries. The rule offered a
46% specificity (95% CI, 41–52), not different from the one in the derivation study. However, the sensitivity significantly
decreased to 64% (95%CI, 50–76), leading to a difference of 20% (95%CI, 17–36). In all, 16 (34%) patients among the 47 with
VUR $3 were misdiagnosed by the rule. This lack of reproducibility might result primarily from a difference between
derivation and validation populations regarding inflammatory parameters (CRP, PCT); the validation set samples may have
been collected earlier than for the derivation one.
Conclusions: The rule built to predict VUR $3 had a stable specificity (ie. 46%), but a decreased sensitivity (ie. 64%) because
of the time variability of PCT measurement. Some refinement may be warranted.
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Introduction
During the past decade, many European and American
pediatric societies have recommended that all young children
undergo a cystography after a first febrile UTI [1,2]. This
systematic strategy is driven by the belief that VUR, especially
moderate and high-grade VUR, is a risk factor for recurrent UTI,
then renal scarring and long-term complications, such as recurrent
infection, hypertension, poor renal growth, and eclampsia [3]. The
systematic strategy is also based on the premise that VUR can be
treated and/or children followed to keep them free of complica-
tions [1,2]. However, even if systematic cystography offered a
nearly 100% sensitivity to identify reflux, it is a truly non-selective
strategy, meaning that many children undergo an unnecessary
cystography, which is painful, irradiating and expensive, and
increases the risk of iatrogenic UTI [4]. Regarding recent
publications minimizing the clinical consequences of low-grade
VUR [5,6], the low rate of high-grade VUR (only 10% of the
children with a first febrile UTI [7]), and the current discussions
on the efficacy of high-grade VUR treatment [6,8,9], some new
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first febrile UTI in children 2 to 24 months old [10,11]. However,
these new guidelines have raised some concerns because of the risk
of delaying high-grade VUR diagnosis [10]. Moreover, definite
evidence about the absence of benefit of antibiotic prophylaxis is
still lacking for many clinical situations because of methodological
weaknesses of the available trials, and this could make the
pendulum swing back towards specific indications of VUR
treatment that have to be diagnosed accurately [12]. Furthermore,
an American study of clinical practices evaluation measured that
only 40% of children who would have benefited from a
cystography actually underwent this examination after a first
UTI, indicating that a more situational approach would likely be
welcomed by parents and clinicians [13].
We believed, then, that there is scope for an evidence-based
strategy, one that offered a moderate alternative to two
diametrically opposed policies (cystography for all or no children).
We derived a predictive tool for moderate and high-grade VUR
(grade $3), aiming to avoid a posteriori unnecessary cystographies
and not to miss those patients with high-grade VUR [14]. This
predictive decision rule includes procalcitonin (PCT), a validated
and sensitive predictor of VUR [15–17], and the ureteral dilation
from renal ultrasonography (US) [18]. PCT was initially studied as
a predictor of VUR because this sensitive biomarker was
demonstrated to correlate with acute pyelonephritis and scars,
both related to VUR [19,20]. The rule indicates that in children
between one month and four years old with a first febrile UTI, a
cystography should be performed in cases with ureteral dilation
(i.e. ureter visible on the renal ultrasonography – US) and a serum
PCT level (measured at the time of UTI diagnosis) $0.17 ng/mL,
or without ureteral dilatation (i.e. ureter not visible on the renal
US) when the serum PCT level $0.63 ng/mL [14]. This rule
yielded 86% (95%CI: 74–93) sensitivity with 47% (95%CI: 42–51)
specificity; the internal mathematical validation confirmed the
derivation predictive ability. However, four steps are involved in
the development of a clinical decision rule: the creation of the rule,
internal validation, external reproducibility, and assessment of its
impact on clinical behavior [21]. Our aim was to evaluate the
reproducibility of the prediction rule that we have developed and
to perform its external validation.
Results
Patients’ characteristics
Eight centres were included [18,22–31]. In all centres, patients
underwent a radiological cystography, and had a PCT measure-
ment with the LUMItest PCT immunoluminometric assay or the
BRAHMS PCT-Q semiquantitative rapid test (BRAHMS AG,
Hennigsdorf, Germany). Half of the centres collected urine with
suprapubic aspiration or urethral catheterization for non-toilet
trained children, and half used sterile bags (Table 1).
Of the 530 who met the inclusion criteria, 417 were finally
included in the analysis (Figure 1). The mean age of the children
was 11.9 months (SD: 10.7, median: 8.5, Inter-quartile - IQR:
4.0–16.0); 157 (38%) were boys. VUR was diagnosed in 109 (26%)
children and 47 (11%) patients had VUR $3. No adverse event
was reported in performing PCT measurement, renal US nor
cystography. Table 1 provides details on the characteristics of each
centre population.
Validity of the rule
When applying the rule to the validation population, 16 (34%)
of the 47 patients with VUR $3 were misdiagnosed because they
presented with either ureteral dilation and PCT ,0.17 ng/mL
(for one patient – 2%) or without ureteral dilation and PCT
,0.63 ng/mL (for the 15–32% - other patients - Figures 2 and 3).
We did not find a significant relationship between VUR $3 and
the clinical decision rule: adjusted OR=1.5 (95% CI, 0.7–3.4);
P=0.3. On the validation population, the decision rule yielded a
64% (95% CI, 40–76) sensitivity, and a 46% (95% CI, 41–52)
specificity (Table 2). Specificity and positive predictive value (46%
and 13% respectively) were not significantly different from the
derivation set (47%, and 17% respectively), whereas sensitivity and
negative predictive value were (64% and 91 respectively for the
validation set vs. 86% and 96% respectively for the derivation set-
Table 2).
When applying the rounded rule and the rule based on PCT
alone to the validation population, we also found a non-significant
relationship between VUR $3 and the rule, as well as a significant
decrease of sensitivity and negative predictive value (Table 2).
In the subgroup of children for whom urine specimens were
collected using suprapubic aspiration or urethral catheterization
for non-toilet trained children, the relationships between VUR $3
and the rules were not significant (Table 3). For the three rules,
sensitivities did not differ from those found in the entire population
(60 (95% CI, 39–78) in the subgroup vs. 64 (95% CI, 50–76) for
the entire set for the exact rule), whereas specificities were
significantly higher: 58 (95% CI, 51–65) in the subgroup vs. 46
(95% CI, 41–52) for the entire set for the exact rule (Table 3).
Comparison of the derivation and validation populations
Because we did not find the similar results between derivation
and validation populations, we compared their characteristics.
There was no significant difference regarding gender, prevalence
of all-grade or high-grade VUR, distribution of age (Table 4).
However, CRP was significantly lower in the validation population
compared with the derivation population: median=53.8 mg/L
(IQR: 20.0–98.0) vs. 77.5 mg/L (IQR: 38.0–140.0), P ,0.001.
PCT had a trend close to significance to be lower for children with
VUR $3 in the validation set compared with those in the
derivation set: median=1.5 ng/mL (IQR: 0.3–6.1) vs. 2.9 (IQR:
1.2–6.8); P=0.06. There was also a trend to find more ureteral
dilations on renal US in children with VUR ,3 in the validation
set compared with the derivation one: 23 (6%) vs. 16 (4%),
P=0.08.
Discussion
We report the first attempt to evaluate the reproducibility of the
decision rule based on PCT and ureteral dilation proposed by our
group [14]. In the derivation study, a significant relationship was
found between VUR $3 and the rule (P ,0.0001), even when
considering the rounded rule, or the rule based on PCT only.
These significant relationships were not found again in the
validation set (P .0.1). The 47% specificity (95%CI, 42–51) of the
rule for the prediction of VUR $3 was confirmed (46%; 95%CI,
41–52), but not the sensitivity: 60% (95% CI, 50–76) in the
validation set vs. 86% (95% CI, 74–93) in the derivation
population. The results were similarly comparable between
validation and derivation populations for the rounded rule and
the rule based on PCT only. Applying the rule to the validation
set, we would not have prescribed cystography, and then
misdiagnosed VUR in 16 patients (15 without ureteral dilation),
representing 34% of the patients with VUR $3. The rule only had
missed 9 (16%) children among those with VUR $3 in the
derivation study [14].
The first issue to be addressed to investigate the decreases of
predictive ability of a rule is the difference in the derivation and
High-Grade Vesico-Ureteral Prediction in Children
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could not be transferred across those sets of patients [21]. In the
present case, populations were not significantly different (P .0.05)
for the classic parameters: gender, prevalence of all-grade and
high-grade of VUR. Nevertheless, the validation population had a
significantly lower level of inflammatory biomarkers: for CRP for
all children, in PCT was also lower in children with VUR $3.
This result means that the entire distribution of PCT values was
moved towards lower values for children with high-grade VUR in
the validation population; it could explain why the group of 15
(94%) out of 16 patients with VUR$3 were missed by the rule,
and thus belonged to the rule branch of ‘‘patients without ureteral
dilation and PCT ,0.63 ng/mL’’. As the weight of the rule is
mainly carried by PCT, a lowest distribution of PCT values might
have a major influence on the results of the rule validation set; it is
demonstrated by that 15 (94%) out of the 16 patients missed by the
rule were not rescued by ureteral dilation criterion. Indeed, this
hypothesis also may explain why even the rule based on PCT
alone failed to reproduce the 85% sensitivity, even though this
result had previously been validated in two multicentre cohort
studies [16,17]. This significant difference in inflammatory
biomarkers distributions between validation and derivation sets
could be due to the fact that samples were collected at different
time points during UTI course. We were not able to verify this
Table 1. Population characteristics according to each center.
Centre
*
Urine collection techniques
(threshold of the positive bacteriuria)
{ n
Male n
(%)
Age median
(IQR)
All-grade
VUR n (%)
Grade $3
VUR n (%)
CRP Median
(IQR)
Centres using SA or UC (n=199)
Alex. SA (any), UC (10
4), CVM (10
5) 40 9 (23) 10.5 (6.5–12.5) 12 (30) 8 (20) 57.0 (14.5–91.0)
Athens SA (10
3), UC (10
4), CVM (10
5) 52 26 (50) 6.6 (3.0–9.8) 10 (19) 0 (0) 42.4 (6.1–108)
Barcelona SA (any), UC (5.10
4), CVM (10
5) 55 22 (41) 6.0 (3.0–9.0) 13 (24) 4 (7) 44.6 (14.1–76.7)
Elazig UC (10
3), CVM (10
5) 52 25 (48) 6.0 (6.0–36.0) 3 (6) 0 (0) 12.5 (4–40)
Centres using SB (n=213)
Lille SB (10
5) 23 7 (29) 8.5 (4.0–19.0) 14 (58) 3 (13) 52.5 (19–83)
Padova SB (10
5) 47 17 (38) 6.4 (3.1–11.4) 9 (19) 2 (4) 61.0 (37–120)
Paris SB (10
5) 52 23 (44) 7.6 (2.8–12.8) 13 (25) 5 (10) 85.0 (53.6–117)
Toulouse SB (10
5), CVM (10
5) 91 28 (31) 9.2 (5.3–17.7) 35 (38) 17 (19) 75.5 (33.0–117)
Total (n=413) 413 157 (38) 8.5 (4.0–16.0) 109 (26) 47 (11) 53.8 (20–98)
*Classified according to the urine collection technique in non-toilet-trained children.
{In colony-forming units/mL.
Abbreviations: Alex for Alexandroupolis; CRP, C-reactive protein; CVM, Clean-voided midstream; IQR, Interquartile range; SA, Suprapubic aspiration; SB, Sterile bag; UC,
Urethral catheterization; VUR, Vesicoureteral reflux.
doi:10.1371/journal.pone.0029556.t001
Figure 1. Diagnosis tree and distribution of the study population at each step of the decision rule in the validation population.
Abbreviations: PCT, Procalcitonin; VUR, Vesico-ureteral reflux.
doi:10.1371/journal.pone.0029556.g001
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inflammatory markers measurement from the appearance of
fever, and this data was not collected. Further study of this time
interval would be necessary to improve this rule and to implement
it safely. These differences regarding the inflammatory parameters
distributions were unpredictable before the study validation,
because all centres were European and applied the same standard
procedures to diagnose and treat children with UTI. Moreover,
there was also a trend (p=0.08) in the difference between
derivation and validation sets on the ureteral dilation on renal US
Figure 2. Distribution of Procalcitonin values according to the presence of high-grade VUR and the presence of Ureteral dilation on
renal ultrasonography.
doi:10.1371/journal.pone.0029556.g002
Figure 3. Distribution of Procalcitonin values according to the
presence of high-grade VUR and the presence of Ureteral
dilation on renal ultrasonography. The horizontal lines are the
dichotomization threshold in each group.
doi:10.1371/journal.pone.0029556.g003
Table 2. Sensitivity and specificity of the decision rule in the
derivation and validation populations.
Derivation
*
(n=494,
prevalence of
VUR $3: 11%)
Validation
(n=413,
prevalence of
VUR $3: 11%) Difference
{
Clinical decision rule
aOR
** 5.2 (2.4–11.3) 1.5 (0.7–3.4)
Sensitivity 86 (74–93) 64 (50–76) 22 (5 to 38)
Specificity 47 (42–51) 46 (41–52) 0 (27t o7 )
PPV 17 (13–22) 13 (10–18) 4 (23 to 10)
NPV 96 (93–98) 91 (86–94) 5 (1 to 11)
Rounded decision rule
aOR
** 6.8 (0.9–50.0) 1.3 (0.6–3.2)
Sensitivity 86 (76–94) 62 (47–74) 26 (9 to 41)
Specificity 44 (40–49) 45 (40–50) 1 (26t o8 )
PPV 17 (13–21) 13 (9–18) 4 (22 to 10)
NPV 97 (93–98) 90 (85–94) 6 (1 to 12)
Rule based on PCT alone
aOR
** 4.9 (2.3–10.6) 1.3 (0.5–3.4)
Sensitivity 86 (74–93) 60 (45–72) 28 (11 to 44)
Specificity 45 (40–50) 46 (41–51) 1 (26t o8 )
PPV 17 (13–21) 12 (9–17) 4 (22 to 10)
NPV 96 (93–98) 90 (85–93) 7 (2 to 12)
Values are expressed as values or % (95% CI).
Discriminative values were compared using a x
2 test for unpaired sample.
*Data in the column come from the previously published derivation of the
decision rule [34].
**Adjusted OR were calculated with the multi-level logistic regression models.
{Differences are rounded to the closer integer.
Abbreviations: NPV, Negative predictive value; OR, Odd ratio; PCT, Procalcitonin;
PPV, Positive predictive value.
doi:10.1371/journal.pone.0029556.t002
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added to the differences between the two populations concerning
the key variables of the rule. Furthermore, we acknowledge that
the rule included ureteral dilation, which is a renal US criterion
with no measurement of its inter-operator variability in a multi-
case multi-reader study, even if it was found to be the best US
renal criterion to predict high-grade VUR [18]. This weakness of
the rule needs to be evaluated and corrected.
The second issue concerning the validation’s difficulties to
reproduce derivation results is the limitations of the external
validation study. The validation was a secondary analysis of
previously published prospective cohort studies, as was the
derivation study. Because our group performed a systematic
review and meta-analysis on PCT in UTI in children, we gathered
the worldwide published data of children with PCT and VUR
[20]. The derivation study was based on the initially published
cohort studies, while the validation study was premised on the later
ones. We did not, however, believe that the structure of these
studies would affect the quality of the data or introduce a bias.
The use of sterile bags for urine collection for the non-toilet
trained children in half of the centres might have introduced a
selection bias, because this technique is less specific than
suprapubic aspiration or urethral catheterization [1]. However,
there was no significant difference in the number of children for
whom urine were collected by sterile bags, compared with those in
the derivation population: 238 (48%) children vs. 214 (52%),
P=0.3 (Table 4). Interestingly, the specificities of the rules were
significantly higher in the subgroup of children for whom urine
specimens were collected properly than in the whole population.
This result can be explained by the lower specificity for UTI
diagnosis of sterile bags compared with recommended techniques.
Indeed, because VUR is known to be a risk factor for UTI, the use
of sterile bags might have increased the number of children with
VUR ,3 more than those with VUR $3. In the same manner,
because PCT is positively correlated with the presence and severity
of UTI [20], and because the weight of the rule was more carried
by PCT than by ureteral dilation [14], the use of sterile bags may
have increased the number of children with a negative result than
Table 3. Sensitivity and specificity of the decision rule in the
whole validation population and in the subgroup of children
for whom urines were collected using suprapubic aspiration,
urethral catheterization or clean-voided midstream sample.
Whole populationSubgroup
* Difference
Clinical decision rule
aOR
** 1.5 (0.7–3.4) 2.0 (0.4–11.6)
Sensitivity 64 (50–76) 60 (39–78) 4 (220 to 28)
Specificity 46 (41–52) 58 (51–65) 11 (2 to 20)
PPV 13 (10–18) 14 (8–22) 1 (21t o7 )
NPV 91 (86–94) 93 (86–96) 2 (21t o8 )
Rounded decision
rule
aOR
** 1.3 (0.6–3.2) 1.9 (0.3–11.1)
Sensitivity 62 (47–74) 60 (39–78) 2 (220 to 26)
Specificity 45 (40–50) 55 (48–62) 10 (1 to 19)
PPV 13 (9–18) 13 (8–21) 0 (21t o7 )
NPV 90 (85–94) 93 (86–96) 2 (25t o9 )
Rule based on PCT
alone
aOR
** 1.3 (0.5–3.4) 1.9 (0.3–11.1)
Sensitivity 60 (45–72) 60 (39–78) 0 (224 to 25)
Specificity 46 (41–51) 56 (49–63) 10 (1 to 18)
PPV 12 (9–17) 13 (8–22) 21( 210 to 7)
NPV 90 (85–93) 93 (86–96) 3 (25t o9 )
Values are expressed as values or % (95% CI).
Discriminative values were compared using a x
2 test for unpaired sample.
*Subgroup of children for who urines were collected using suprapubic
aspiration or urethral catheterization.
**Adjusted OR were calculated with the multi-level logistic regression models.
Abbreviations: NPV, Negative predictive value; OR, Odd ratio; PCT, Procalcitonin;
PPV, Positive predictive value.
doi:10.1371/journal.pone.0029556.t003
Table 4. Comparison of the characteristics of the derivation and validation populations.
Variables
Derivation
* (n=494,
prevalence of VUR $3: 11%)
Validation (n=413,
prevalence of VUR $3: 11%) P-value
**
Use of sterile bags 238 (48) 214 (52) 0.3
Male gender 197 (40) 157 (38) 0.6
All grade VUR 126 (26) 109 (29) 0.8
High-grade VUR 56 (11) 47 (11) 1.0
Age (months) 12.1 (611.2); 8.0 (4.0–17.0) 11.9 (610.7); 8.5 (4.0–16.0) 0.7
CRP (mg/mL) 94.6 (674.0); 77.5 (38.0–140.0) 68.4 (664.1); 53.8 (20.0–98.0) ,0.0001
PCT (ng/mL) 4.2 (619.3); 0.9 (0.3–2.8) 3.5 (68.6); 0.8 (0.3–3.1) 0.5
in children with VUR ,3 3.6 (619.3); 0.7 (0.3–2.4) 3.4 (68.8); 0.8 (0.3–2.5) 1.0
in children with VUR $3 8.3 (618.5); 2.9 (1.2–6.8) 4.4 (66.5); 1.5 (0.3–6.1) 0.06
Ureteral dilation 25 (5) 33 (8) 0.8
in children with VUR ,3 16 (4) 23 (6) 0.08
in children with VUR $3 10 (18) 20 (21) 0.7
Values are expressed as n (%) for binary variables (gender, All grade and high-grade VUR, Ureteral dilation), and as: mean (6Standard deviation); median (inter-quartile
range) for continuous variables (age, CPR, PCT).
*Data in the column come from the previously published derivation of the decision rule [34].
**Binary variables were compared using a x
2 test, and continuous variables were compared using the non-parametric Mann-Whitney test.
Abbreviations: CRP, C-reactive protein; PCT, Procalcitonin; U dilation, Ureteral dilation; VUR, Vesico-ureteral reflux.
doi:10.1371/journal.pone.0029556.t004
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Padova, Italy), in order to decrease the likelihood of false positive
results due to bag urine collection, included only children with two
consecutive positive urine cultures. The combined increases (in the
number of children with VUR ,3 and in the number of children
with PCT ,0.5 ng/mL when sterile bags are used to collected
urine) resulted in an underestimate in the specificity in children for
whom urine were collected by sterile bags, and thus accounts for
the significant difference in specificities. It did not, however,
explain the failure to reproduce the sensitivity of the rule, nor the
loss of a significant relationship between VUR $3 and the rules.
To summarize, the validation study may have had some
limitations, but none of these limitations appeared to explain fully
the failure to validate externally the decision rule.
The validation of the decision rule based on PCT and ureteral
dilation on renal US confirmed the rule specificity, but showed a
loss of its sensitivity, which led to a misdiagnosis of 34% of children
with VUR $3. The fact that the rule performed better in the
derivation population than in the validation one was predictable,
according to the Evidence Based Working Group [21]. However,
the decrease in sensitivity might also be primarily due to
differences regarding PCT distributions between derivation and
validation sets and was thus unpredictable prior to the study. The
rule therefore may need greater refinement, particularly regarding
the time of PCT measurement and the variability between
observers of ureteral dilation. Furthermore, the outcome should
also be reconsidered and modified for a composite outcome,
including high-grade VUR and renal scars, which are precisely the
cause of kidney injuries leading to future complications, and the
real goal of any nephroprotection strategy including VUR
treatment.
Methods
Study design
We conducted a secondary analysis of already published data on
children with UTI, PCT and VUR. Because we had conducted a
systematic review and meta-analysis on individual patient data on
early and late renal scarring and PCT in children with UTI [16],
we knew all the centres possessing data on PCT and VUR in
children with UTI. To perform the external validation of the rule,
we included all centres [18,22–31] that had not been included in
the study to derive the rule [14]. All consecutive children in each
center, aged one month to four years and admitted with a first
febrile UTI (temperature $38uC with a positive bacterial urine
culture defined according to each centre criteria – Table 1) were
considered for inclusion. Children with an already known
uropathy (ie. any urological or urinary tract abnormality, as
posterior urethral valves, ectopic ureter, VUR); at the time of the
UTI diagnosis, those who had received antibiotics in the 48 hours
before diagnosis, and those who had undergone radionuclide
cystography (which does not distinguish high-grade from low-
grade VUR [32]) were not included. Of note, results of antenatal
renal US were not taken into account to include children, insofar
as there was no post-natal diagnostic confirmation before UTI
diagnosis. Because this study was a secondary analysis of already-
published prospective cohort studies, the electronic data files were
merged across studies; informed consent had had already been
obtained for the initial studies.
Outcome definition
All patients had a voiding cystography, the gold standard
examination for the diagnosis and classification of VUR.
Cystographies were read according to the ‘‘International System
of Radiological Grading of Vesicoureteric Reflux’’ [33] by an
experienced senior radiologists in Pediatrics in each centre, and
blinded to PCT and renal US results. Moderate and high-grade
VUR was a priori defined as a VUR grade $3, which means that
VUR extends up to the renal pelvis with an increased ureteral
dilation with the grade of reflux [7].
Definition of predictors included in the rule
Each child’s serum PCT was prospectively measured at
admission for febrile UTI (i.e. when children arrived at the
Emergency Department), with the LUMItest PCT immunolumi-
nometric assay (BRAHMS, Hennigsdorf, Germany). The other
potential predictive variables came from the findings of renal US
performed at the time of UTI diagnosis by an experienced senior
pediatric radiologist blinded to the PCT measurement, and before
cystography was performed: ureteral dilation (defined by ureter
visibility during renal US). The imaging studies were reviewed
blinded to cystography results, and data were extracted from the
radiologist’s record.
Statistical analyses
We first described the study population’s general characteristics.
We then applied the rule to every patient, classifying each one as
cystography recommended or not. We also applied the rounded
rule (i.e. a cystography should performed in case of ureteral
dilation and PCT $0.2 ng/mL, or if PCT $0.6 ng/mL in
absence of ureteral dilation), and the rule based on PCT alone (a
cystography should be prescribed if PCT $0.6 ng/mL) to each
child. We evaluated the relationship between VUR $3 and the
decision rules with an adjusted OR using a multi-level logistic
regression model (where centers were considered as the group level
variable). We then calculated for the clinical decision rule, the
rounded rule, and the rule based on PCT alone, the sensitivity,
specificity, positive and negative predictive values. We ran the
same calculation in the subgroup of children for whom urine
specimens were collected using ‘‘recommended’’ techniques (i.e.
suprapubic aspiration or urethral catheterization for non-toilet
trained children and clean-voided midstream for toilet trained
children). Discriminative values were compared with those of the
derivation population [14]. In case of significant difference, we
compared the characteristics of derivation and validation popu-
lations using x
2 tests and non-parametric Mann-Whitney tests.
Statistical analyses were performed with Stata 11/SE software
(StataCorp, College Station, TX, USA) and Confidence Interval
Analysis software (London, UK).
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